For the quarter ending 2026-03-31, NWBO has $80,051K in assets. $118,111K in debts. $1,786K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 1,786 | 3,040 | 4,560 | 4,316 |
| Prepaid expenses and other current assets | 4,416 | 2,166 | 2,327 | 1,839 |
| Loan receivable | - | 311 | 311 | - |
| Total current assets | 6,202 | 5,517 | 7,198 | 6,155 |
| Property, plant and equipment, net | 16,771 | 17,406 | 16,870 | 16,685 |
| Right-of-use asset, net | 4,050 | 4,197 | 4,265 | 4,419 |
| Indefinite-lived intangible asset | - | - | 1,292 | 1,292 |
| Intangible assets, net | 52,048 | 53,188 | - | - |
| Goodwill | 626 | 626 | 626 | 626 |
| Other assets | 354 | 356 | 358 | 370 |
| Total non-current assets | 73,849 | 75,773 | 23,411 | 23,392 |
| Total assets | 80,051 | 81,290 | 30,609 | 29,547 |
| Contingent payable derivative liability | - | 9,416 | 9,665 | 9,112 |
| Accounts payable and accrued expenses | 31,584 | 30,816 | 26,875 | 23,659 |
| Accounts payable and accrued expenses to related parties and affiliates | - | - | 9,841 | 8,016 |
| Convertible notes, net | 740 | 640 | 818 | 793 |
| Convertible notes at fair value | 30,828 | 32,056 | 26,008 | 24,692 |
| Notes payable, net | 11,650 | 9,468 | 13,570 | 16,313 |
| Warrant liability | - | - | - | 681 |
| Investor advances | 207 | 207 | 207 | 207 |
| Share payable | 370 | 373 | 522 | - |
| Lease liabilities | 274 | 374 | 399 | 448 |
| Due to related party | 7,320 | 8,350 | - | - |
| Total current liabilities | 82,973 | 91,700 | 87,905 | 83,921 |
| Convertible notes, net of current portion | 1,494 | 325 | - | - |
| Convertible notes at fair value, net of current portion | 7,513 | 5,220 | 24,617 | 13,772 |
| Notes payable, net of current portion, net | 7,204 | 12,333 | 7,188 | 9,166 |
| Lease liabilities, net of current portion | 4,291 | 4,411 | 4,447 | 4,624 |
| Contingent payment obligation | 1,700 | 1,700 | 1,700 | 4,700 |
| Deferred tax liability | 12,936 | 13,171 | - | - |
| Total non-current liabilities | 35,138 | 37,160 | 37,952 | 32,262 |
| Total liabilities | 118,111 | 128,860 | 125,857 | 116,183 |
| Series c convertible preferred stock, 10,000,000 shares designated 766,747 shares and 784,347 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively aggregate liquidation preference of 11.0 million | 12,484 | 12,710 | 13,400 | 13,753 |
| Common stock (0.001 par value) 2,600,000,000 shares authorized 1,618.9 million and 1,567.4 million shares issued as of march 31, 2026 and december 31, 2025 1,606.9 million and 1,555.4 million shares outstanding as of march 31, 2026 and december 31, 2025, respectively | 1,619 | 1,567 | 1,518 | 1,459 |
| Treasury stock, 12,000,000 shares at march 31, 2026 and december 31, 2025, respectively | 12 | 12 | - | - |
| Additional paid-in capital | 1,455,087 | 1,442,830 | 1,396,179 | 1,378,300 |
| Stock subscription receivable | 79 | 79 | 79 | 79 |
| Accumulated deficit | -1,506,730 | -1,503,661 | -1,505,049 | -1,478,220 |
| Accumulated other comprehensive loss | -429 | -925 | -1,217 | -1,849 |
| Total stockholders' deficit | -50,544 | -60,280 | -108,648 | -100,389 |
| Total liabilities, mezzanine equity and stockholders' deficit | 80,051 | 81,290 | 30,609 | 29,547 |
NORTHWEST BIOTHERAPEUTICS INC (NWBO)
NORTHWEST BIOTHERAPEUTICS INC (NWBO)